expression of biological activity. It is conceivable that alterations in molecular size and configuration, without alterations in amino-acid composition or sequence, might activate or inactivate biologically (physically, physiochemically, physiologically and immunologically) reactive sites. One may ask: 'What is a pure pituitary hormone?' (1964) Brit 
Excretion of Gonadotrophin and

Sensitivity to Follicle-stimulating Hormone
We have observed a wide variation between patients in sensitivity to treatment with human pituitary follicle-stimulating hormone (HPFSH).
We have estimated the ED501 by the method of Spearman & Karber (Finney 1952) for each of 14 patients with hypothalamic amenorrhoea and 8 with anovular menstruation. In both groups the means of the ED50 and the scatter were similar, the latter extending over about a tenfold range. No reason for the difference between patients was found in their histories or clinical findings but it was thought that a relationship might exist between the amount of gonadotrophin excreted in 1ED50: that dose producing a response in 50% of trials (Fig 3) failed to respond to the highest dose we have ever used despite a progressive fall in excretion of gonadotrophins from the postmenopausal level to the low normal range. This result is even more surprising since treatment was delayed until after the gonadotrophin excretion had fallen spontaneously to a low level. We have no explanation for these findings. They do not support the belief that the cause lies in the pituitary since gonadotrophins were being excreted in the urine of all the patients. It is possible, however, that the rhythmical ebb and flow of HPFSH and luteinizing hormone (HPLH) characteristic of normal menstruation is lost or diminished in these patients, or that the normally changing ratio of HPFSH to HPLH is defective. These changes are believed to depend on hypothalamic stimulation but our methods ofmeasuring HPFSH or HPLH must be improved before an adequate study of this problem can be undertaken. Serial hormone assays in urine have been used to study the effect of clomiphene on endocrine function in 2 patients with the Stein-Leventhal syndrome, 2 patients with secondary amenorrhoea, 2 normal men and one man with Addison's disease maintained on therapy with dexamethasone and fluorohydrocortisone. In one of the patients with secondary amenorrhcea the structurally related compound chlorotrianisene (TACE) was also administered.1
In the patients with the Stein-Leventhal syndrome and secondary amenorrhoea clomiphene stimulated ovarian function and ovulation as judged by urinary steroid assays, the most consistent change produced being an increase in the output of cestrogens. Ovarian stimulation occurred without any marked alteration in pituitary gonadotrophin excretion as measured by the mouse uterus test. In the one patient with secondary amenorrhea treated with TACE little or no effect on hormone output was noted.
In normal male subjects clomiphene caused a marked rise in neutral steroid excretion together with an increase in the output of cestrone, cestradiol and cestriol; the gonadotrophin output was virtually unchanged during treatment. The rise in cestrone excretion was more marked and tended to occur earlier than the increase in aestriol output. In the patient with Addison's disease the most striking change produced by clomiphene was a marked rise in the levels of urinary testosterone and of its main metabolites, androsterone and aetiocholanolone.
The evidence presented is compatible with the view that clomiphene acts directly on the target glandsovaries, testes and adrenalsrather than on the anterior pituitary. However, a definite conclusion regarding the site of action of the drug cannot be offered until specific and practicable assays for the determination of follicle-stimulating hormone and luteinizing hormone separately become available for application to problems of this type..
